QAD Enterprise Applications Enterprise Edition facilitated speedy
compliance for the Chinese market
Aesica is a leading pharmaceutical contract development and manufacturing organization (CDMO). The company, operating in a highly regulated industry, had to meet product serialization and tracking regulations to maintain customer safety, while fighting drug counterfeiting, streamlining the recall process and minimizing financial loss.
“QAD has been a great partner to help Aesica meet the unexpectedly accelerated deadline from China,” said
Working with QAD,
With the successful implementation, Aesica can now:
Aesica Pharmaceuticals S.r.l. supplies contract development and contract manufacturing services for finished dose and active pharmaceutical ingredients to the world’s leading pharmaceutical companies and emerging biotechnology organizations. With headquarters in the
For media enquiries, please contact
About QAD – The Effective Enterprise
For more information about QAD, call +1 805-566-6000 or visit www.qad.com.
“QAD” is a registered trademark of
Note to Investors: This press release contains certain forward-looking statements made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expects”, “believes”, “anticipates”, “could”, “will likely result”, “estimates”, “intends”, “may”, “projects”, “should”, “would”, “might”, “plan” and variations of these words and similar expressions are intended to identify these forward looking statements. Forward-looking statements are based on the company’s current expectations and assumptions regarding its business, the economy and future conditions. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to, evolving demand for the company's software products and products that operate with the company's products; the company's ability to sustain license and service demand; the company's ability to leverage changes in technology; the company's ability to sustain customer renewal rates at current levels; the publication of opinions by industry and financial analysts about the company, its products and technology; the reliability of estimates of transaction and integration costs and benefits; the entry of new competitors or new offerings by existing competitors and the associated announcement of new products and technological advances by them; delays in localizing the company's products for new or existing markets; the ability to recruit and retain key personnel; delays in sales as a result of lengthy sales cycles; changes in operating expenses, pricing, timing of new product releases, the method of product distribution or product mix; timely and effective integration of newly acquired businesses; general economic conditions; exchange rate fluctuations; and, the global political environment. In addition, revenue and earnings in the enterprise resource planning (ERP) software industry are subject to fluctuations. Software license revenue, in particular, is subject to variability with a significant proportion of revenue earned in the last month of each quarter. Given the high margins associated with license revenue, modest fluctuations can have a substantial impact on net income. Investors should not use any one quarter's results as a benchmark for future performance. For a more detailed description of the risk factors associated with the company and the industries in which it operates, please refer to the company's Annual Report on Form 10-K for its fiscal year ended